Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Free Cash Flow (2016 - 2025)

Conmed (CNMD) has disclosed Free Cash Flow for 16 consecutive years, with $41.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 4.9% year-over-year to $41.2 million, compared with a TTM value of $150.9 million through Dec 2025, down 1.95%, and an annual FY2025 reading of $150.9 million, down 1.95% over the prior year.
  • Free Cash Flow was $41.2 million for Q4 2025 at Conmed, down from $48.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $51.5 million in Q4 2023 and bottomed at -$17.3 million in Q4 2022.
  • Average Free Cash Flow over 5 years is $26.0 million, with a median of $28.8 million recorded in 2021.
  • The sharpest move saw Free Cash Flow soared 2046.76% in 2021, then crashed 156.46% in 2022.
  • Year by year, Free Cash Flow stood at $30.6 million in 2021, then tumbled by 156.46% to -$17.3 million in 2022, then soared by 398.37% to $51.5 million in 2023, then dropped by 23.75% to $39.3 million in 2024, then grew by 4.9% to $41.2 million in 2025.
  • Business Quant data shows Free Cash Flow for CNMD at $41.2 million in Q4 2025, $48.5 million in Q3 2025, and $23.4 million in Q2 2025.